Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNK-396 in Elevated LDL-C
NCT05896969Phase 1Completed
- Sponsor
- Syneos Health
- Start
- Apr 2023
- Primary completion
- Feb 2024
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SNK-396 in hypercholesterolemia (2 cohorts), sponsored by Syneos Health. Primary endpoint: Treatment emergent adverse events at Day 85. Started Apr 2023; status: completed.
02
Drugs
SNK-396
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT05896969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05896969.